Sun Pharma Q3 PAT may rise 49.6% at Rs 1318cr: ICICIdirect

ICICIdirect.com has come out with its October-December quarter earnings estimates for the healthcare sector. The brokerage house expects Sun Pharmaceutical Industries to report a 3.2 percent degrowth quarter-on-quarter (up 49.6 percent Y-o-Y) in net profit at Rs 1318.6 crore.

Revenue of Sun Pharmaceutical Industries is expected to increase by 0.7 percent Q-o-Q (down 47.9 percent Y-o-Y) to Rs 4236.8 crore, according to ICICIdirect.com.

Earnings before interest, tax, depreciation and amortisation (EBITDA) are likely to fall by 2.2 percent Q-o-Q (up 41.5 percent Y-o-Y) to Rs 1803.1 crore.

ICICIdirect.com on Sun Pharmaceutical Industries:

Sun Pharma is expected to post robust growth of 42 percent on the back of 75 percent growth in the US formulations and 18 percent growth in the domestic formulations. Even excluding sales from URL Pharma (recently acquired company) the US growth is likely to be robust at 52 percent YoY. EBITDA margins may decline by 190 bps YoY to 42.6 percent on higher base.

Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.